Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Arbutus Biopharma ( (ABUS) ) has provided an announcement.
In March 2026, Arbutus, Genevant and Moderna entered a global patent litigation settlement under which Moderna paid a noncontingent lump sum of $950 million, with Arbutus receiving about $178 million on July 8, 2026 including litigation cost reimbursement. The deal also left room for a contingent payment of up to $1.3 billion tied to a limited appeal under 28 U.S.C. §1498 and separate U.S. government claims filed in March 2026, highlighting Arbutus’ reliance on IP enforcement as a revenue source.
On July 15, 2026 Arbutus terminated a prior agreement with Genevant related to Moderna’s RSV vaccine in exchange for a $1 million fee, and its board approved sizable one-time litigation-linked bonuses for CEO Lindsay Androski and CFO Tuan Nguyen. These awards, keyed to proceeds from the Moderna settlement and ongoing Pfizer/BioNTech patent suits, underscore how the litigation windfall is reshaping executive compensation and capital allocation, with Arbutus signaling plans to return up to about $230 million to shareholders via share repurchases after an expected Q3 2026 dividend from Genevant’s parent.
The most recent analyst rating on (ABUS) stock is a Buy
with a $7.00 price target.
To see the full list of analyst forecasts on Arbutus Biopharma stock,
see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
The score is driven primarily by mixed financial quality (strong balance sheet but ongoing cash burn and volatile earnings quality), supported by positive corporate catalysts (FDA Fast Track and the Moderna settlement). Technicals add moderate near-term support, while the very low P/E improves the valuation picture but may reflect non-recurring earnings.
To see Spark’s full report on ABUS stock,
click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, with a core emphasis on therapies for chronic hepatitis B. Its pipeline includes the RNAi therapeutic imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101), and it also derives strategic value from lipid nanoparticle (LNP) delivery technology licensed to Genevant Sciences, which underpins ongoing IP enforcement against major mRNA vaccine makers.
Through its collaboration with Genevant, Arbutus is positioned at the intersection of infectious disease drug development and mRNA delivery platforms, using litigation and licensing to monetize its LNP portfolio. The company’s market focus spans hepatitis B treatment and broader applications of its LNP technology in vaccines, giving it exposure to both traditional biopharma markets and the fast-evolving mRNA therapeutics space.
Average Trading Volume: 2,142,859
Technical Sentiment Signal: Strong Buy
Current Market Cap: $900.8M
For a thorough assessment of ABUS stock, go to TipRanks’ Stock Analysis page.